Kawasaki Disease - Market Insight, Epidemiology and Market Forecast - 2028
![](/report_cover/8047/kawasaki-disease-market-insights-epidemiology-n-market-forecast-v-2025_en.gif)
This report can be delivered to the clients within 7-10 Business Days
DelveInsight's 'Kawasaki Disease - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Kawasaki Disease epidemiology and market outlook for the 7MM.
MARKETS COVERED
Kawasaki Disease Understanding and Treatment Algorithm
The market report provides the overview of the Kawasaki Disease by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.
Kawasaki Disease Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Kawasaki Disease in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
Kawasaki Disease Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.
Kawasaki Disease Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Kawasaki Disease market.
Kawasaki Disease Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.
Kawasaki Disease Report Insights
DelveInsight's 'Kawasaki Disease - Market Insight, Epidemiology and Market Forecast - 2028' report provides a detailed analysis of the Kawasaki Disease epidemiology and market outlook for the 7MM.
MARKETS COVERED
- United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Kawasaki Disease Understanding and Treatment Algorithm
The market report provides the overview of the Kawasaki Disease by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology and diagnostic methods. It also covers the detailed treatment approaches and therapy areas under research and development for 7MM.
Kawasaki Disease Epidemiology
The report provides a comprehensive account of the total patient pool, diagnosed cases and potential patient pool eligible for the treatment. It also includes the explanation of changing trends of epidemiology after evaluating numerous studies, survey reports and views of key opinion leaders. The Report provides the 10 years forecast from 2016 to 2028 segmented by seven major markets, enabling to understand the potential of the Kawasaki Disease in the respective markets. The epidemiology data is presented with graphs and tables to provide a clear assessment of the landscape.
Kawasaki Disease Product Profiles & Analysis
The drug chapter segment covers the complete analysis of marketed drugs and Phase III & late Phase II pipeline drugs. This division focuses on the recent breakthroughs like clinical development analysis, agreements and collaborations, clinical trial details, allotted designations, published results, pharmacological effects, patent expiry, and expected launch timings. Moreover, advantages and disadvantages of the therapy along with opinion of experts for marketed and emerging drugs are also provided.
Kawasaki Disease Market Outlook
The report’s market outlook delivers an understanding of the country-specific revenue and share by analyzing the performance of the current therapies and potential uptake of new products. The in-depth analysis helps to recognize the growing demand of the market by evaluating the annual cost of therapy, compliance rate, competition with other therapies, covered patient segment, impact of emerging technology in the forecast period. The views from the key opinion leaders adds more value to the analysis. This segment provides the relevant graphs and tables to have an effective outline of the Kawasaki Disease market.
Kawasaki Disease Market Share by Therapies
This division provides an understanding of the rate of drug uptake, drugs including both recently launched and those which show potential to get launched during the forecast period from 2016-2028. The analysis is based on patient uptake by therapies, sales projection of each drug by studying the reasons behind the maximal use of new drugs. A comparative analysis is also done on the basis of market share and size by assessing the drugs uptake to project the drug positioning in the market.
Kawasaki Disease Report Insights
- Patient Population in Kawasaki Disease
- Therapeutic Approaches in Kawasaki Disease
- Kawasaki Disease Pipeline Analysis
- Kawasaki Disease Market Size and Trends
- Kawasaki Disease Market Opportunities
- Impact of upcoming Therapies in Kawasaki Disease
- 10 Year Forecast
- 7MM Coverage
- Epidemiology Segmentation
- Drugs Uptake
- Highly Analyzed Market
- Key Cross Competition
- Current Treatment Practices in Kawasaki Disease
- Unmet Needs in Kawasaki Disease
- Market Attractiveness
- Market Drivers and Barriers
- The report will help to develop Business Strategies by understanding the trends shaping and driving the Kawasaki Disease market
- Organize sales and marketing efforts by identifying the best opportunities for Kawasaki Disease market
- To understand the future market competition in the Kawasaki Disease market.
1. REPORT INTRODUCTION
2. KAWASAKI DISEASE MARKET OVERVIEW AT A GLANCE
2.1. Market Share Distribution of Kawasaki Disease in 2016
2.2. Market Share Distribution of Kawasaki Disease in 2028
3. DISEASE BACKGROUND AND OVERVIEW: KAWASAKI DISEASE
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Kawasaki Disease in 7MM
4.3. Total Prevalent Patient Population of Kawasaki Disease in 7MM – By Countries
5. EPIDEMIOLOGY OF KAWASAKI DISEASE BY COUNTRIES
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Kawasaki Disease
5.1.3. Sub-Type Specific cases of the Kawasaki Disease
5.1.4. Sex- Specific Cases of the Kawasaki Disease
5.1.5. Diagnosed Cases of the Kawasaki Disease
5.1.6. Treatable Cases of the Kawasaki Disease
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Kawasaki Disease
5.4.3. Sub-Type Specific cases of the Kawasaki Disease
5.4.4. Sex- Specific Cases of the Kawasaki Disease
5.4.5. Diagnosed Cases of the Kawasaki Disease
5.4.6. Treatable Cases of the Kawasaki Disease
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Kawasaki Disease
5.5.3. Sub-Type Specific cases of the Kawasaki Disease
5.5.4. Sex- Specific Cases of the Kawasaki Disease
5.5.5. Diagnosed Cases of the Kawasaki Disease
5.5.6. Treatable Cases of the Kawasaki Disease
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Kawasaki Disease
5.6.3. Sub-Type Specific cases of the Kawasaki Disease
5.6.4. Sex- Specific Cases of the Kawasaki Disease
5.6.5. Diagnosed Cases of the Kawasaki Disease
5.6.6. Treatable Cases of the Kawasaki Disease
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Kawasaki Disease
5.7.3. Sub-Type Specific cases of the Kawasaki Disease
5.7.4. Sex- Specific Cases of the Kawasaki Disease
5.7.5. Diagnosed Cases of the Kawasaki Disease
5.7.6. Treatable Cases of the Kawasaki Disease
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Kawasaki Disease
5.8.3. Sub-Type Specific cases of the Kawasaki Disease
5.8.4. Sex- Specific Cases of the Kawasaki Disease
5.8.5. Diagnosed Cases of the Kawasaki Disease
5.8.6. Treatable Cases of the Kawasaki Disease
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Kawasaki Disease
5.9.3. Sub-Type Specific cases of the Kawasaki Disease
5.9.4. Sex- Specific Cases of the Kawasaki Disease
5.9.5. Diagnosed Cases of the Kawasaki Disease
5.9.6. Treatable Cases of the Kawasaki Disease
6. CURRENT TREATMENT & MEDICAL PRACTICES
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. UNMET NEEDS OF THE KAWASAKI DISEASE
8. MARKETED THERAPIES
8.1. Drug A: Company
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. PIPELINE THERAPIES – AT A GLANCE
10. KEY CROSS COMPETITION
11. EMERGING THERAPIES FOR KAWASAKI DISEASE
11.1. Drug C: Company
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. KAWASAKI DISEASE: 7MM MARKET ANALYSIS
12.1. 7MM Market Size of Kawasaki Disease
12.2. 7MM Percentage Share of drugs marketed for Kawasaki Disease
12.3. 7MM Market Sales of Kawasaki Disease by Products
13. KAWASAKI DISEASE: COUNTRY-WISE MARKET ANALYSIS
13.1. United States
13.1.1. Market Size of Kawasaki Disease in United States
13.1.2. Percentage Share of drugs marketed for Kawasaki Disease in United States
13.1.3. Market Sales of Kawasaki Disease by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Kawasaki Disease in Germany
13.2.1.2. Percentage Share of drugs marketed for Kawasaki Disease in Germany
13.2.1.3. Market Sales of Kawasaki Disease by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Kawasaki Disease in France
13.2.2.2. Percentage Share of drugs marketed for Kawasaki Disease in France
13.2.2.3. Market Sales of Kawasaki Disease by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Kawasaki Disease in Italy
13.2.3.2. Percentage Share of drugs marketed for Kawasaki Disease in Italy
13.2.3.3. Market Sales of Kawasaki Disease by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Kawasaki Disease in Spain
13.2.4.2. Percentage Share of drugs marketed for Kawasaki Disease in Spain
13.2.4.3. Market Sales of Kawasaki Disease by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Kawasaki Disease in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Kawasaki Disease in United Kingdom
13.2.5.3. Market Sales of Kawasaki Disease by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Kawasaki Disease in Japan
13.3.2. Percentage Share of drugs marketed for Kawasaki Disease in Japan
13.3.3. Market Sales of Kawasaki Disease by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
17. REPORT METHODOLOGY
17.1. Sources
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
Indication Specific
2. KAWASAKI DISEASE MARKET OVERVIEW AT A GLANCE
2.1. Market Share Distribution of Kawasaki Disease in 2016
2.2. Market Share Distribution of Kawasaki Disease in 2028
3. DISEASE BACKGROUND AND OVERVIEW: KAWASAKI DISEASE
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. EPIDEMIOLOGY AND PATIENT POPULATION
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Kawasaki Disease in 7MM
4.3. Total Prevalent Patient Population of Kawasaki Disease in 7MM – By Countries
5. EPIDEMIOLOGY OF KAWASAKI DISEASE BY COUNTRIES
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Kawasaki Disease
5.1.3. Sub-Type Specific cases of the Kawasaki Disease
5.1.4. Sex- Specific Cases of the Kawasaki Disease
5.1.5. Diagnosed Cases of the Kawasaki Disease
5.1.6. Treatable Cases of the Kawasaki Disease
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Kawasaki Disease
5.4.3. Sub-Type Specific cases of the Kawasaki Disease
5.4.4. Sex- Specific Cases of the Kawasaki Disease
5.4.5. Diagnosed Cases of the Kawasaki Disease
5.4.6. Treatable Cases of the Kawasaki Disease
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Kawasaki Disease
5.5.3. Sub-Type Specific cases of the Kawasaki Disease
5.5.4. Sex- Specific Cases of the Kawasaki Disease
5.5.5. Diagnosed Cases of the Kawasaki Disease
5.5.6. Treatable Cases of the Kawasaki Disease
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Kawasaki Disease
5.6.3. Sub-Type Specific cases of the Kawasaki Disease
5.6.4. Sex- Specific Cases of the Kawasaki Disease
5.6.5. Diagnosed Cases of the Kawasaki Disease
5.6.6. Treatable Cases of the Kawasaki Disease
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Kawasaki Disease
5.7.3. Sub-Type Specific cases of the Kawasaki Disease
5.7.4. Sex- Specific Cases of the Kawasaki Disease
5.7.5. Diagnosed Cases of the Kawasaki Disease
5.7.6. Treatable Cases of the Kawasaki Disease
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Kawasaki Disease
5.8.3. Sub-Type Specific cases of the Kawasaki Disease
5.8.4. Sex- Specific Cases of the Kawasaki Disease
5.8.5. Diagnosed Cases of the Kawasaki Disease
5.8.6. Treatable Cases of the Kawasaki Disease
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Kawasaki Disease
5.9.3. Sub-Type Specific cases of the Kawasaki Disease
5.9.4. Sex- Specific Cases of the Kawasaki Disease
5.9.5. Diagnosed Cases of the Kawasaki Disease
5.9.6. Treatable Cases of the Kawasaki Disease
6. CURRENT TREATMENT & MEDICAL PRACTICES
6.1. Treatment Algorithm
6.2. Treatment Guidelines
7. UNMET NEEDS OF THE KAWASAKI DISEASE
8. MARKETED THERAPIES
8.1. Drug A: Company
8.1.1. Drug Description
8.1.2. Mechanism of Action
8.1.3. Regulatory Milestones
8.1.4. Advantages & Disadvantages
8.1.5. Product Profile
8.2. Drug B: Company
8.2.1. Drug Description
8.2.2. Mechanism of Action
8.2.3. Regulatory Milestones
8.2.4. Advantages & Disadvantages
8.2.5. Product Profile
9. PIPELINE THERAPIES – AT A GLANCE
10. KEY CROSS COMPETITION
11. EMERGING THERAPIES FOR KAWASAKI DISEASE
11.1. Drug C: Company
11.1.1. Drug Description
11.1.2. Clinical Trials Details
11.1.3. Safety and Efficacy Profile
11.1.4. Advantages & Disadvantages
11.1.5. Pipeline Development Activities
11.1.6. Product Profile
11.2. Drug D: Company
11.2.1. Drug Description
11.2.2. Clinical Trials Details
11.2.3. Safety and Efficacy Profile
11.2.4. Advantages & Disadvantages
11.2.5. Pipeline Development Activities
11.2.6. Product Profile
12. KAWASAKI DISEASE: 7MM MARKET ANALYSIS
12.1. 7MM Market Size of Kawasaki Disease
12.2. 7MM Percentage Share of drugs marketed for Kawasaki Disease
12.3. 7MM Market Sales of Kawasaki Disease by Products
13. KAWASAKI DISEASE: COUNTRY-WISE MARKET ANALYSIS
13.1. United States
13.1.1. Market Size of Kawasaki Disease in United States
13.1.2. Percentage Share of drugs marketed for Kawasaki Disease in United States
13.1.3. Market Sales of Kawasaki Disease by Products in United States
13.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2. EU-5
13.2.1. Germany
13.2.1.1. Market Size of Kawasaki Disease in Germany
13.2.1.2. Percentage Share of drugs marketed for Kawasaki Disease in Germany
13.2.1.3. Market Sales of Kawasaki Disease by Products in Germany
13.2.1.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.2. France
13.2.2.1. Market Size of Kawasaki Disease in France
13.2.2.2. Percentage Share of drugs marketed for Kawasaki Disease in France
13.2.2.3. Market Sales of Kawasaki Disease by Products in France
13.2.2.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.3. Italy
13.2.3.1. Market Size of Kawasaki Disease in Italy
13.2.3.2. Percentage Share of drugs marketed for Kawasaki Disease in Italy
13.2.3.3. Market Sales of Kawasaki Disease by Products in Italy
13.2.3.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.4. Spain
13.2.4.1. Market Size of Kawasaki Disease in Spain
13.2.4.2. Percentage Share of drugs marketed for Kawasaki Disease in Spain
13.2.4.3. Market Sales of Kawasaki Disease by Products in Spain
13.2.4.4. Analysis of Upcoming Therapies and their Impact on the Market
13.2.5. United Kingdom
13.2.5.1. Market Size of Kawasaki Disease in United Kingdom
13.2.5.2. Percentage Share of drugs marketed for Kawasaki Disease in United Kingdom
13.2.5.3. Market Sales of Kawasaki Disease by Products in United Kingdom
13.2.5.4. Analysis of Upcoming Therapies and their Impact on the Market
13.3. Japan
13.3.1. Market Size of Kawasaki Disease in Japan
13.3.2. Percentage Share of drugs marketed for Kawasaki Disease in Japan
13.3.3. Market Sales of Kawasaki Disease by Products in Japan
13.3.4. Analysis of Upcoming Therapies and their Impact on the Market
14. MARKET DRIVERS
15. MARKET BARRIERS
16. APPENDIX
17. REPORT METHODOLOGY
17.1. Sources
18. DELVEINSIGHT CAPABILITIES
19. DISCLAIMER
20. ABOUT DELVEINSIGHT
Indication Specific
LIST OF TABLES
Table 1: Total Prevalent/Incident Cases of the Kawasaki Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Kawasaki Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Kawasaki Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Kawasaki Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Kawasaki Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Kawasaki Disease in United States (2016-2028)
Table 7: Treatable Cases of the Kawasaki Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Kawasaki Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Kawasaki Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Kawasaki Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Kawasaki Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Kawasaki Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Kawasaki Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Kawasaki Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Kawasaki Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Kawasaki Disease in France (2016-2028)
Table 17: Treatable Cases of the Kawasaki Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Kawasaki Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Kawasaki Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Kawasaki Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Kawasaki Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Kawasaki Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Kawasaki Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Kawasaki Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Kawasaki Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Kawasaki Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Kawasaki Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Kawasaki Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Kawasaki Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Kawasaki Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Kawasaki Disease in UK (2016-2028)
Table 32: Treatable Cases of the Kawasaki Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Kawasaki Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Kawasaki Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Kawasaki Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Kawasaki Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Kawasaki Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 45: United States-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 51: France-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 60:UK-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 1: Total Prevalent/Incident Cases of the Kawasaki Disease in 7MM
Table 2: Total Prevalent/Incident Cases of the Kawasaki Disease in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Kawasaki Disease in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Kawasaki Disease in United States (2016-2028)
Table 5: Sex- Specific Cases of the Kawasaki Disease in United States (2016-2028)
Table 6: Diagnosed Cases of the Kawasaki Disease in United States (2016-2028)
Table 7: Treatable Cases of the Kawasaki Disease in United States (2016-2028)
Table 8: Prevalent/Incident Cases of the Kawasaki Disease in Germany (2016-2028)
Table 9: Sub-Type Specific cases of the Kawasaki Disease in Germany (2016-2028)
Table 10: Sex- Specific Cases of the Kawasaki Disease in Germany (2016-2028)
Table 11: Diagnosed Cases of the Kawasaki Disease in Germany (2016-2028)
Table 12: Treatable Cases of the Kawasaki Disease in Germany (2016-2028)
Table 13: Prevalent/Incident Cases of the Kawasaki Disease in France (2016-2028)
Table 14: Sub-Type Specific cases of the Kawasaki Disease in France (2016-2028)
Table 15: Sex- Specific Cases of the Kawasaki Disease in France (2016-2028)
Table 16: Diagnosed Cases of the Kawasaki Disease in France (2016-2028)
Table 17: Treatable Cases of the Kawasaki Disease in France (2016-2028)
Table 18: Prevalent/Incident Cases of the Kawasaki Disease in Italy (2016-2028)
Table 19: Sub-Type Specific cases of the Kawasaki Disease in Italy (2016-2028)
Table 20: Sex- Specific Cases of the Kawasaki Disease in Italy (2016-2028)
Table 21: Diagnosed Cases of the Kawasaki Disease in Italy (2016-2028)
Table 22: Treatable Cases of the Kawasaki Disease in Italy (2016-2028)
Table 23: Prevalent/Incident Cases of the Kawasaki Disease in Spain (2016-2028)
Table 24: Sub-Type Specific cases of the Kawasaki Disease in Spain (2016-2028)
Table 25: Sex- Specific Cases of the Kawasaki Disease in Spain (2016-2028)
Table 26: Diagnosed Cases of the Kawasaki Disease in Spain (2016-2028)
Table 27: Treatable Cases of the Kawasaki Disease in Spain (2016-2028)
Table 28: Prevalent/Incident Cases of the Kawasaki Disease in UK (2016-2028)
Table 29: Sub-Type Specific cases of the Kawasaki Disease in UK (2016-2028)
Table 30: Sex- Specific Cases of the Kawasaki Disease in UK (2016-2028)
Table 31: Diagnosed Cases of the Kawasaki Disease in UK (2016-2028)
Table 32: Treatable Cases of the Kawasaki Disease in UK (2016-2028)
Table 33: Prevalent/Incident Cases of the Kawasaki Disease in Japan (2016-2028)
Table 34: Sub-Type Specific cases of the Kawasaki Disease in Japan (2016-2028)
Table 35: Sex- Specific Cases of the Kawasaki Disease in Japan (2016-2028)
Table 36: Diagnosed Cases of the Kawasaki Disease in Japan (2016-2028)
Table 37: Treatable Cases of the Kawasaki Disease in Japan (2016-2028)
Table 38: Marketed Therapies
Table 39: Emerging Therapies
Table 40: Key Cross Competition
Table 41:7MM- Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 42:7MM- Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 43:7MM- Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 44: United States-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 45: United States-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 46: United States-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 47: Germany-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 48: Germany-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 49: Germany-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 50: France-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 51: France-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 52: France-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 53: Italy-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 54: Italy-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 55: Italy-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 56: Spain-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 57: Spain-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 58: Spain-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 59:UK-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 60:UK-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 61:UK-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 62: Japan-Market Size of Kawasaki Disease in USD MM (2016-2028)
Table 63: Japan-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Table 64: Japan-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
LIST OF FIGURES
Figure 1: Total Prevalent/Incident Cases of the Kawasaki Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Kawasaki Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Kawasaki Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Kawasaki Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Kawasaki Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Kawasaki Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Kawasaki Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Kawasaki Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Kawasaki Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Kawasaki Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Kawasaki Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Kawasaki Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Kawasaki Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Kawasaki Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Kawasaki Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Kawasaki Disease in France (2016-2028)
Figure 17: Treatable Cases of the Kawasaki Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Kawasaki Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Kawasaki Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Kawasaki Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Kawasaki Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Kawasaki Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Kawasaki Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Kawasaki Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Kawasaki Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Kawasaki Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Kawasaki Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Kawasaki Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Kawasaki Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Kawasaki Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Kawasaki Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Kawasaki Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Kawasaki Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Kawasaki Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Kawasaki Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Kawasaki Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Kawasaki Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 51: France-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 1: Total Prevalent/Incident Cases of the Kawasaki Disease in 7MM
Figure 2: Total Prevalent/Incident Cases of the Kawasaki Disease in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Kawasaki Disease in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Kawasaki Disease in United States (2016-2028)
Figure 5: Sex- Specific Cases of the Kawasaki Disease in United States (2016-2028)
Figure 6: Diagnosed Cases of the Kawasaki Disease in United States (2016-2028)
Figure 7: Treatable Cases of the Kawasaki Disease in United States (2016-2028)
Figure 8: Prevalent/Incident Cases of the Kawasaki Disease in Germany (2016-2028)
Figure 9: Sub-Type Specific cases of the Kawasaki Disease in Germany (2016-2028)
Figure 10: Sex- Specific Cases of the Kawasaki Disease in Germany (2016-2028)
Figure 11: Diagnosed Cases of the Kawasaki Disease in Germany (2016-2028)
Figure 12: Treatable Cases of the Kawasaki Disease in Germany (2016-2028)
Figure 13: Prevalent/Incident Cases of the Kawasaki Disease in France (2016-2028)
Figure 14: Sub-Type Specific cases of the Kawasaki Disease in France (2016-2028)
Figure 15: Sex- Specific Cases of the Kawasaki Disease in France (2016-2028)
Figure 16: Diagnosed Cases of the Kawasaki Disease in France (2016-2028)
Figure 17: Treatable Cases of the Kawasaki Disease in France (2016-2028)
Figure 18: Prevalent/Incident Cases of the Kawasaki Disease in Italy (2016-2028)
Figure 19: Sub-Type Specific cases of the Kawasaki Disease in Italy (2016-2028)
Figure 20: Sex- Specific Cases of the Kawasaki Disease in Italy (2016-2028)
Figure 21: Diagnosed Cases of the Kawasaki Disease in Italy (2016-2028)
Figure 22: Treatable Cases of the Kawasaki Disease in Italy (2016-2028)
Figure 23: Prevalent/Incident Cases of the Kawasaki Disease in Spain (2016-2028)
Figure 24: Sub-Type Specific cases of the Kawasaki Disease in Spain (2016-2028)
Figure 25: Sex- Specific Cases of the Kawasaki Disease in Spain (2016-2028)
Figure 26: Diagnosed Cases of the Kawasaki Disease in Spain (2016-2028)
Figure 27: Treatable Cases of the Kawasaki Disease in Spain (2016-2028)
Figure 28: Prevalent/Incident Cases of the Kawasaki Disease in UK (2016-2028)
Figure 29: Sub-Type Specific cases of the Kawasaki Disease in UK (2016-2028)
Figure 30: Sex- Specific Cases of the Kawasaki Disease in UK (2016-2028)
Figure 31: Diagnosed Cases of the Kawasaki Disease in UK (2016-2028)
Figure 32: Treatable Cases of the Kawasaki Disease in UK (2016-2028)
Figure 33: Prevalent/Incident Cases of the Kawasaki Disease in Japan (2016-2028)
Figure 34: Sub-Type Specific cases of the Kawasaki Disease in Japan (2016-2028)
Figure 35: Sex- Specific Cases of the Kawasaki Disease in Japan (2016-2028)
Figure 36: Diagnosed Cases of the Kawasaki Disease in Japan (2016-2028)
Figure 37: Treatable Cases of the Kawasaki Disease in Japan (2016-2028)
Figure 38: Marketed Therapies
Figure 39: Emerging Therapies
Figure 40: Key Cross Competition
Figure 41:7MM- Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 42:7MM- Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 43:7MM- Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 44: United States-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 45: United States-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 46: United States-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 47: Germany-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 48: Germany-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 49: Germany-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 50: France-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 51: France-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 52: France-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 53: Italy-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 54: Italy-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 55: Italy-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 56: Spain-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 57: Spain-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 58: Spain-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 59:UK-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 60:UK-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 61:UK-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 62: Japan-Market Size of Kawasaki Disease in USD MM (2016-2028)
Figure 63: Japan-Market Share Kawasaki Disease by Therapies in USD MM (2016-2028)
Figure 64: Japan-Market Sales of Kawasaki Disease by Therapies in USD MM (2016-2028)